PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Prices as of the 2026-10-02 close
Having wound down its biotech division to focus on CRO and quality-analysis services, Invites Biocore continues to post small operating profits, but a sharply shrinking equity base means the company faces both a KOSDAQ move-listing push and a capital-adequacy challenge at the same time.
Consolidated operating profit was KRW 218 million in 2025, a second straight profitable year after KRW 326 million in 2024, though the margin remains thin at around 1%.
Total equity collapsed from KRW 39.9 billion in 2023 to KRW 13.9 billion in 2024 and KRW 2.7 billion in 2025, pushing the debt ratio up to 3,018.1%.
The company reclassified its biotech division as a discontinued operation in FY2025 and restructured around its CRO and quality-analysis businesses.
Under its '2026 Scale-Up Execution Guideline,' the company has set a target of completing a KOSDAQ fast-track move-listing within 2027.
Overhang concerns stem from the maturity of KONEX-era venture funds that entered in 2015-2016, and the company has been responding with measures including block-deal arrangements.
Invites Biocore is a clinical research organization (CRO) founded in 2001 and listed on the KONEX market in 2015. Its core businesses are pharmaceutical development research, genetic analysis, and specialty analysis, offered through CRO services and quality-analysis services.
The company positions itself around its experience as Korea's first GLP-certified toxicokinetics analysis institute and has partnerships with global firms including Pfizer and IQVIA, serving more than 150 clients.
It previously also operated a biotech division handling genetic and sequencing-based diagnostic testing along with DNA/protein chip and PCR kit development, which at one point generated revenue comparable in scale to its other units.
That division accounted for KRW 8.7 billion, or 40.4%, of total 2024 revenue, but the board resolved in April 2025 to discontinue it, and it was classified as a discontinued operation in the FY2025 financial statements amid falling profitability and a broader business restructuring.
Following the wind-down, the company has said it is expanding clinical and analytical testing services centered on its CRO segment while pursuing new markets such as late-stage clinical trials and digital therapeutics (DTx).
The quality-analysis unit has expanded services in response to growing demand for pharmaceutical quality control and operates alongside CRO as a core business.
In terms of ownership, the largest shareholder is Invites Genomics, and the company is affiliated through the private-equity-led 'Invites Ecosystem,' which also has cross-shareholding ties with KOSDAQ-listed CG Invites.
| Quarter | Revenue | Operating profit | Op. margin |
|---|
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2023 | ₩22.3B | -₩5.3B | -₩8.2B | −24.0% | −32.8% | 185.8% |
| 2024 | ₩21.6B | ₩300M | -₩10.8B | 1.5% | −77.6% | 607.0% |
| 2025 | ₩16.6B | ₩200M | -₩8.3B | 1.3% | −312.7% | 3018.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
On a confirmed consolidated basis, revenue declined from KRW 22.3 billion in 2023 to KRW 21.6 billion in 2024 and KRW 16.6 billion in 2025. Much of this contraction reflects the reclassification of the discontinued biotech division's revenue out of the reported top line.
Data provider FnGuide, by contrast, states that on a year-over-year basis for FY2025, consolidated revenue rose 29.0%, operating profit turned positive, and net loss narrowed 22.4%, but that figure is calculated on a continuing-operations basis and covers a different scope than the total consolidated figures used here.
Operating profit swung from a large loss of KRW 5.3 billion (an operating margin of -24.0%) in 2023 to a profit of KRW 326 million (1.5%) in 2024 and KRW 218 million (1.3%) in 2025, marking two consecutive profitable years, albeit with thin margins.
Indeed, revenue from the biotech segment fell sharply from KRW 8.7 billion in 2024 to about KRW 800 million last year, while its operating result swung from a profit of roughly KRW 800 million to a loss of about KRW 600 million over the same period, and separating this segment out as discontinued operations is what allows the continuing-operations consolidated operating line to show a modest profit.
Net loss attributable to owners, meanwhile, widened from KRW 8.2 billion in 2023 to KRW 10.8 billion in 2024 before narrowing to KRW 8.3 billion in 2025, suggesting that losses tied to discontinued operations and non-operating items continue to weigh on the bottom line despite the operating-level turnaround.
The most notable concern is total equity, which plunged from KRW 39.9 billion in 2023 (KRW 24.9 billion attributable to owners, KRW 15.0 billion to non-controlling interests) to KRW 13.9 billion in 2024 and just KRW 2.7 billion in 2025, driving the debt ratio up from 185.8% to 607.0% and then to 3,018.1%.
Operating cash flow, however, remained positive throughout — KRW 1.1 billion in 2023, KRW 7.0 billion in 2024, and KRW 7.2 billion in 2025 — indicating a gap between reported accounting losses and underlying cash generation.
The global CRO industry is expected to see continued growth as AI adoption expands across the drug development process and GLP-1 class therapeutics broaden their indications.
FnGuide notes that AI technology has become embedded across the entire drug development process, and as GLP-1-based therapeutics expand their indications, the global CRO market is projected to grow at a 10.5% CAGR to reach USD 108.2 billion by 2027.
Domestically, expanding outsourcing by pharmaceutical companies seeking to reduce R&D costs is cited as a structural factor supporting CRO demand.
Invites Biocore positions itself in this market on the strength of being an early domestic analytical institute with GLP certification in toxicokinetics, leveraging partnerships with global firms such as Pfizer and IQVIA to build credibility.
That said, the company is a relatively small player compared to large global CROs and listed domestic competitors in terms of revenue scale, putting it at a relative disadvantage in economies of scale.
The broader 'Invites Ecosystem' to which the company belongs aims to build a vertically integrated healthcare platform spanning CRO, genomic analysis, digital healthcare, and hospital operations, and has been pursuing the acquisition of a general hospital in Guam (GRMC) through affiliate CG Invites.
That acquisition is reported to have already cleared approval from the U.S.
Committee on Foreign Investment in the United States (CFIUS), suggesting the group's overseas footprint expansion is advancing, though this is an affiliate-level event whose direct impact on Invites Biocore's own consolidated results is likely limited.
The company has presented an execution roadmap toward a KOSDAQ move-listing under its '2026 Scale-Up Execution Guideline'.
Specifically, it stated it would make growth momentum visible in areas such as DTx digital clinical commercialization in the second quarter of this year and begin full preparations for the move-listing in the first half of next year, followed by accumulating results in the second half of next year through CRO/quality analysis and digital healthcare expansion, with the goal of completing the KOSDAQ move-listing within 2027.
The financial requirement for the KOSDAQ fast-track move-listing is an operating profit of at least KRW 1 billion for KONEX-listed companies, and the company said it has adjusted its standalone operating profit target to around KRW 1.7 billion, above that threshold.
However, Invites Biocore has a track record of setbacks, having pursued move-listings in 2021 and 2023 only to fail due to a voluntary withdrawal of a SPAC merger and insufficient qualitative requirements such as shareholding structure and growth potential, meaning this attempt's outcome will hinge not only on meeting financial criteria but also on passing qualitative review.
The company is also addressing overhang risk, stating that to ease share-price volatility, it would begin measures from the end of this month to resolve potential overhang from pending sell positions, aiming to use block-deal arrangements to manage share supply tied to the maturity of long-term funds that entered in 2015-2016.
In parallel, it is pursuing a shareholding structure realignment intended to insulate its consolidated financials from deteriorating performance at affiliate CG Invites.
On the operating side, the company is reportedly seeking to lower costs through external partnerships rather than direct capital investment in capital-intensive areas such as GLP and CSV facilities, and has begun early-stage exploration of entry into the European digital healthcare market.
Invites Biocore has posted net losses for three straight years, making profit-based valuation metrics difficult to derive, and with no dividend track record, a dividend-yield comparison is likewise not applicable.
Because total equity has shrunk sharply over the past two years, the net-asset base against which the share price is compared has itself become structurally smaller, meaning the price-to-book ratio sits in a range shaped heavily by that capital contraction.
Operating profit shifted direction from a large loss in 2023 to consecutive profits in 2024 and 2025, but margins remain thin, so it is still premature to draw simple comparisons between profit scale and market capitalization.
Given the limited trading volume and lower liquidity typical of the KONEX market, price volatility tied to shifts in market participant supply and demand is also a factor to weigh.
With multiple corporate actions — the move-listing push, overhang-resolution measures, and an affiliate shareholding restructuring — proceeding simultaneously, any valuation discussion should be considered alongside the progress of these non-operating events.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
Operating profit turned from a large loss of KRW 5.3 billion in 2023 to profits of KRW 326 million in 2024 and KRW 218 million in 2025, marking two consecutive profitable years.
This can be interpreted as reflecting the effect of discontinuing the loss-generating biotech division and refocusing the business on CRO and quality-analysis services. That said, margins remain thin at around 1%, so the absolute scale of profit is still modest.
Even amid ongoing net losses, operating cash flow stayed positive for three consecutive years — KRW 1.1 billion in 2023, KRW 7.0 billion in 2024, and KRW 7.2 billion in 2025.
This indicates a gap between accounting losses and actual cash-generating capacity, likely reflecting the payment-collection structure typical of CRO and quality-analysis service businesses.
Through its '2026 Scale-Up Execution Guideline,' the company has laid out a concrete timeline: preparation in the first half of 2026, results accumulation in the second half, and completion of a KOSDAQ move-listing within 2027.
It has stated a standalone operating profit target of KRW 1.7 billion, above the KRW 1 billion fast-track requirement, signaling intent to meet the financial criteria. Concrete execution steps, including overhang resolution and affiliate share purchases, are also proceeding in parallel.
Total equity plunged from KRW 39.9 billion in 2023 to KRW 13.9 billion in 2024 and just KRW 2.7 billion in 2025. As a result, the debt ratio soared from 185.8% to 607.0% and then to 3,018.1%, significantly weakening the company's financial buffer.
Without additional capital raising, continued losses could bring capital-impairment-related issues into sharper focus.
Net loss attributable to owners persisted for three straight years — KRW 8.2 billion in 2023, KRW 10.8 billion in 2024, and KRW 8.3 billion in 2025. The fact that net losses continued despite an operating-profit turnaround suggests non-operating factors, including discontinued-operations losses, have persisted.
Indeed, the biotech segment swung from a profit of KRW 800 million in 2024 to a loss of KRW 600 million in 2025 before being wound down, illustrating significant volatility in a unit that once accounted for over 40% of total revenue.
The company was assessed 2.5 penalty points by the exchange for disclosing the discontinuation of its biotech division a year and three months after the board's resolution. Such disclosure delays could weigh on qualitative assessments of management transparency while the company is preparing for a KOSDAQ move-listing.
In addition, governance-related risks exist around its complex shareholding relationship with affiliate CG Invites and the maturity of pledged shares.
While total equity has shrunk to around KRW 2.7 billion, total liabilities stand at KRW 80.1 billion, pushing the debt ratio to 3,018.1%. If net losses continue, capital-impairment-related issues could come into focus and affect both continued listing and move-listing requirements. Whether and when additional capital is raised will be an important factor to watch.
The company has twice attempted a move-listing, in 2021 and 2023, only to be turned back due to insufficient qualitative requirements such as shareholding structure and growth potential.
Even if it meets the financial requirement of an operating profit above KRW 1 billion, it still faces the challenge of passing qualitative review, and the recent late-disclosure penalty history could also weigh on that qualitative assessment.
The company holds shares in affiliate CG Invites within the Invites Ecosystem, and pledges tied to those shares mature on December 23, 2026.
There is potential for the affiliate's deteriorating performance to affect consolidated financials, alongside overhang concerns tied to the maturity of funds that entered in 2015-2016, meaning the company faces both governance and supply-demand risks simultaneously.
Check whether the affiliate-level acquisition of the GRMC hospital in Guam (linked to CG Invites) is completed, and when its results begin to be reflected in the broader Invites Ecosystem's consolidated figures.
This is the maturity date for three CG Invites share pledge agreements tied to Dasan Networks; watch for changes in affiliate shareholding structure and overhang risk around this date.
Track the actual progress of overhang-resolution measures (such as block deals) tied to the maturity of funds that entered in 2015-2016, and the remaining scale of pending sell positions.
Check whether preparations for the KOSDAQ move-listing accelerate as outlined in the company's roadmap, and whether the standalone operating profit target of KRW 1.7 billion is met.
The FY2026 audit report and business report disclosure will offer the first full-year look at performance and equity trends following the wind-down of the biotech division.
Invites Biocore has posted two consecutive years of operating profit after winding down its biotech division and refocusing on CRO and quality-analysis services, but behind that lies a weakened financial structure, with total equity plunging to KRW 2.7 billion and the debt ratio soaring to 3,018.1%.
Operating cash flow has remained consistently positive, a notable gap between accounting losses and actual cash-generating capacity worth keeping in mind.
The company has laid out a concrete roadmap targeting a KOSDAQ move-listing within 2027 under its '2026 Scale-Up Execution Guideline,' alongside parallel execution steps such as overhang resolution and an affiliate shareholding restructuring.
However, two prior move-listing attempts failed due to insufficient qualitative requirements, and a recent penalty for delayed disclosure remains a variable in how this attempt will be reviewed going forward.
The shareholding relationship with affiliate CG Invites and the share pledge maturity scheduled for December 2026 are also factors that warrant continued attention.
Investors should weigh the improving direction of operating profit against the contrasting signal of shrinking total equity, and track upcoming disclosures on move-listing procedures and financial-metric changes as they unfold.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.